newsfilter
← Latest News
Business Wire·

Baxalta Supports Research to Raise Awareness of Treatment Burden on Patients during the Sixth Annual World Primary Immunodeficiency Week

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today celebrates progress and reaffirms its commitment to supporting the global primary immunodeficiency (PI) community during the sixth annual World PI Week, April 22-29, 2016. As part of the company’s ongoing efforts to deliver new solutions to help improve the lives of people with PI, the company is supporting a new research initiative that will assess the major factors contributing to the burden of treatment for patients managing these chronic immune disorders.